Quantcast
Last updated on April 21, 2014 at 5:04 EDT

Latest NCIC Clinical Trials Group Stories

2012-09-05 02:32:26

SEATTLE, Sept. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that an ongoing Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer will be expanded to include an additional group of up to 25 patients whose disease has begun to progress while receiving abiraterone (Zytiga®) and prednisone. PX-866 is Oncothyreon's small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K),...

2012-06-05 02:27:45

--Company to Host Conference Call to Discuss Randomized Phase II Program-- CALGARY, June 5, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with advanced or metastatic non-small cell lung cancer ("NSCLC"). "This agreement...

2011-12-12 21:53:32

New research led by the NCIC Clinical Trials Group (CTG) at Queen´s University has proven patients with limited stage Hodgkin´s lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen as opposed to radiation-based treatment. “These results will influence current treatment practices and lead to more patients being treated with chemotherapy alone,” says Dr. Ralph Meyer, professor of oncology at Queen´s and director of the...

2011-09-12 07:05:00

SEATTLE, WA, Sept. 12, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. The open label Phase 2 trial is being conducted by the NCIC Clinical Trials Group...